20.95
+1.21%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mycenax Biotech
Its shares trade on Taipei Exchange under the ticker 4726.TWO. It has been listed since 30 October 2008. In the fiscal year to 31 December 2025, it reported revenue of TWD 740.2m and a net loss of TWD 448.6m. At that date it held total assets of TWD 3.26bn and shareholders' equity of TWD 1.60bn.
Mycenax Biotech, Inc. engages in the research and development, manufacture, and sale of biopharmaceutical products. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2008-10-30. Its products are derived from mammalian cell culture and microbial fermentation. Its products include TuNEX, LusiNEX, GranNEX and AiNEX. Its products are applied in treatment of brain cancer, psoriasis and renal cell carcinoma, among others. The firm is also engaged in the provision of chemical, manufacturing and control (CMC) technology and the operation of a current good manufacture practice (cGMP) biopharmaceutical factory. The firm mainly operates its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Oct 2008
- Employees
- 25
- Website
- mycenax.com.tw ↗
Leadership
Pay as last reported
- Ms. Peijun ChenChairman of the Board, General Manager, since 2019
- Liru YeAssistant General Manager of Finance and Accounting, Corporate Governance Officer
- Jingying ChenDeputy General Manager, since 2019
- Junhong ChenDirector
- Mr. Hiroshi ItoDirector
- Mr. Ming-Lian KuoDirector
- Yixin LiDirector
- Mr. Jung Chin LinDirector, since 2004
- Enzi LiuDirector
- Ms. Su-Chi WangDirector
- Mr. Yusheng CaiIndependent Director
- Guobin GaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Zhubei, Hsinchu with a focus on biopharmaceutical R&D and manufacturing.
- Operates a cGMP biopharmaceutical factory for product production.
- Offers a range of products including TuNEX, LusiNEX, GranNEX, and AiNEX.
Weaknesses
- Limited to domestic market operations with no specific mention of international expansion.
- Small employee count of 25 indicates limited operational scale.
- No information provided on financial performance or market share.
Opportunities
- Potential for expanding product applications to treat additional conditions like brain cancer and psoriasis.
- Growth in biotechnology sector could increase demand for biopharmaceutical products.
- International market expansion could be explored beyond current domestic focus.
Threats
- Dependence on domestic market may limit growth opportunities.
- Small operational scale could hinder competitiveness against larger firms.
- Lack of financial data makes assessing stability challenging.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.